Research sponsored by Novo Nordisk — the drugmaker that sells semaglutide as an antidiabetic and weight management treatment — found that among 131 study participants who took the drug, 95 noticed a reduced weight by at least 5 percent. The enrolled participants were between 12 and 18 years old, had at least one-weight related condition and were obese or overweight.
Both the placebo group and semaglutide group went through lifestyle intervention, but 11 of the 62 people in the placebo group, or 18 percent, reported a significant weight loss.
Novo Nordisk’s brand-name drugs, Wegovy and Ozempic, are already in short supply because of increased demand, which could be because they’re trending on TikTok and endorsed by celebrities, including Elon Musk.
FDA data shows the supply for Ozempic will be disrupted for the next few weeks because of increased demand, and Wegovy supply is expected to return to normal levels by the end of 2022.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
